X-Aptamer Selection and Validation

  • Ganesh L. Lokesh
  • Hongyu Wang
  • Curtis H. Lam
  • Varatharasa Thiviyanathan
  • Nancy Ward
  • David G. Gorenstein
  • David E. Volk
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1632)

Abstract

Aptamers and second generation analogs, such as X-Aptamers (XAs), SOMAmers, locked nucleic acids (LNAs), and others are increasingly being used for molecular pathway targeting, biomarker discovery, or disease diagnosis by interacting with protein targets on the surface of cells or in solution. Such targeting is being used for imaging, diagnostic evaluation, interference of protein function, or delivery of therapeutic agents. Selection of aptamers using the original SELEX method is cumbersome and time-consuming, often requiring 10–15 rounds of selection, and provides aptamers with a limited number of functional groups, namely four bases of DNA or RNA, although newer SELEX methods have increased this diversity. In contrast, X-Aptamers provide an unlimited number of functional groups and thus are superior targeting agents. Here, we discuss the X-Aptamer selection process.

Key words

Aptamer X-Aptamer Molecular targeting Biotin labeling Dye labeling Bead-based selection Split-pool synthesis Drug aptamer conjugation Aptamer nanoparticle conjugation Aptamer siRNA chimeras Chemical cross-linking Proteomics 

References

  1. 1.
    Tuerk C, Gold L (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249:505–510CrossRefPubMedGoogle Scholar
  2. 2.
    Ellington A, Szostak J (1990) In vitro selection of RNA molecules that bind specific ligands. Nature 346:818–822CrossRefPubMedGoogle Scholar
  3. 3.
    Yang X, Wang H, Beasley DWC, Volk DE, Zhao X, Luxon BA, Lomas LO, Herzog NK, Aronson JF, Barrett ADT, Leary JF, David G, Gorenstein DG (2006) Selection of thioaptamers for diagnostics and therapeutics. Ann N Y Acad Sci 1082(1):116–119CrossRefPubMedGoogle Scholar
  4. 4.
    Cho EJ, Joo-Woon Lee J-W, Ellington AD (2009) Applications of aptamers as sensors. Annu Rev Anal Chem 2:241–264CrossRefGoogle Scholar
  5. 5.
    Keefe AD, Pai P, Ellington A (2010) Aptamers as therapeutics. Nat Rev Drug Discov 9:537–550CrossRefPubMedGoogle Scholar
  6. 6.
    Kang KN, Lee YS (2013) RNA aptamers: a review of recent trends and applications. Adv Biochem Eng Biotechnol 131:153–169PubMedGoogle Scholar
  7. 7.
    Sun H, Zhu X, Lu PY, Rosato RR, Tan W, Zu Y (2014) Oligonucleotide aptamers: new tools for targeted cancer therapy. Mol Ther Nucleic Acids 3:e182CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Blind M, Blank M (2015) Aptamer selection technology and recent advances. Mol Ther Nucleic Acids 4:e223CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Lapa SA, Chudinov AV, Timofeev EN (2016) The toolbox for modified aptamers. Mol Biotechnol 58(2):79–92CrossRefPubMedGoogle Scholar
  10. 10.
    Obika S, Nanbu D, Hari Y, Morio K-I, In Y, Ishida T, Imanishi T (1997) Synthesis of 2′-O,4′-C-methyleneuridine and -cytidine. Novel bicyclic nucleosides having a fixed C3′-endo sugar puckering. Tetrahedron Lett 38(50):8735–8738CrossRefGoogle Scholar
  11. 11.
    Koshkin AA, Singh SK, Nielsen P, Rajwanshi VK, Kumar R, Meldgaard M, Olsen CE, Wengel J (1998) LNA (locked nucleic acids): synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition. Tetrahedron 54(14):3607–3011CrossRefGoogle Scholar
  12. 12.
    Rhie A, Kirby L, Sayer N, Wellesley R, Disterer P, Sylvester I, Gill A, Hope J, William James W, Tahiri-Alaoui A (2003) Characterization of 2′-fluoro-RNA aptamers that bind preferentially to disease-associated conformations of prion protein and inhibit conversion. J Biol Chem 278:39697–39705CrossRefPubMedGoogle Scholar
  13. 13.
    Biesecker G, Dihel L, Enney K, Bendele RA (1999) Derivation of RNA aptamer inhibitors of human complement C5. Immunopharmacology 42:219–230CrossRefPubMedGoogle Scholar
  14. 14.
    Yang X, Fennewald S, Luxon BA, Aronson J, Herzog NK, Gorenstein DG (1999) Aptamers containing thymidine 3′-O-phosphorodithioates: synthesis and binding to nuclear factor-κB. Bioorg Med Chem Lett 9:3357–3362CrossRefPubMedGoogle Scholar
  15. 15.
    Volk DE, Yang X, Fennewald SM, King DJ, Bassett SE, Venkitachalam S, Herzog N, Luxon BA, David G, Gorenstein DG (2002) Solution structure and design of dithiophosphate backbone aptamers targeting transcription factor NF-κB. Bioorg Chem 30(6):396–419CrossRefPubMedGoogle Scholar
  16. 16.
    Volk DE, Power TD, Gorenstein DG, Luxon B (2002) An ab initio study of phosphorothioate and phosphorodithioate interactions with sodium cation. Tetrahedron Lett 43(25):4443–4447CrossRefGoogle Scholar
  17. 17.
    Anderson KM, Nguyen D, Esadze A, Zandrashvili L, Gorenstein DG, Iwahara J (2015) A chemical approach for site-specific identification of NMR signals from protein side-chain NH3+ groups forming intermolecular ion pairs in protein-nucleic acid complexes. J Biomed NMR 62:1–5CrossRefGoogle Scholar
  18. 18.
    Ferguson MR, Rojo DR, Somasunderam A, Thiviyanathan V, Ridley B, Yang X, Gorenstein DG (2006) Delivery of double-stranded DNA thioaptamers into HIV-1 infected cells for antiviral activity. Biochem Biophys Res Commun 344(3):792–797CrossRefPubMedGoogle Scholar
  19. 19.
    Kang J, Lee MS, Watowich SJ, Gorenstein DG (2007) Combinatorial selection of a RNA thioaptamer that binds to Venezuelan Equine Encephalitis virus capsid protein. FEBS Lett 581(13):2497–2502CrossRefPubMedGoogle Scholar
  20. 20.
    Gandham SHA, Volk DE, Lokesh GLR, Neerathilingam M, Gorenstein DG (2014) Thioaptamers targeting dengue virus type-2 envelope protein domain III. Biochem Biophys Res Commun 453(3):309–315CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Mann AP, Somasunderam A, Nieves-Alicea R, Li X, Hu A, Sood AK, Ferrari M, Gorenstein DG, Tanaka T (2010) Identification of thioaptamer ligand against E-selectin: potential application for inflamed vasculature imaging. PLoS One 5(9):e13050CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Somasunderam A, Thiviyanathan V, Tanaka T, Li X, Neerathilingam M, Lokesh GL, Mann A, Peng Y, Ferrari M, Klostergaard J, Gorenstein DG (2010) Combinatorial selection of DNA thioaptamers targeted to the HA binding domain of CD44. Biochemistry 49:9106–9112CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    He W, Elizondo-Riojas M-A, Li X, Lokesh GLR, Somasunderam A, Thiviyanathan V, Volk DE, Durland RH, Englehardt J, Cavasotto CN, Gorenstein DG (2012) X-Aptamers: a bead-based selection method for random incorporation of drug-like moieties onto next-generation aptamers for enhanced binding. Biochemistry 51(42):8321–8323CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Kang J, Lee MS, Copland JA, Luxon BA, Gorenstein DG (2008) Combinatorial selection of a single stranded DNA thioaptamer targeting TGF-beta-1 protein. Bioorg Med Chem Lett 18(6):1835–1839CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Mann AP, Bhavane RC, Somasunderam A, Montalvo-Ortiz BL, Ghaghada KB, Volk D, Nieves-Alicea R, Suh KS, Ferrari M, Annapragada A, Gorenstein DG, Tanaka T (2011) Thioaptamer conjugated liposomes for tumor vasculature targeting. Oncotarget 2(4):298–304CrossRefPubMedGoogle Scholar
  26. 26.
    Mann AP, Somasunderam A, Liu X, Gorenstein DG, Ferrari M (2011) E-selectin-targeted porous silicon particle for nanoparticle delivery to the bone marrow. Adv Mater 23(36):H278–H282CrossRefPubMedGoogle Scholar
  27. 27.
    Tanaka T, Kang S-A, Hasan N, Mann AP, Zheng W, Zhao L, Zhao D, Suh KS, Volk D, Gorenstein DG, Cristofanilli M, Rui H (2015) Blocking the adhesion cascade at the pre-metastatic niche for prevention of breast cancer metastasis. Mol Ther 23(6):1044–1054CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Mai J, Huang Y, Mu C, Zhang G, Xu R, Guo X, Xia X, Volk DE, Lokesh GL, Thiviyanathan V, Gorenstein DG, Liu X, Ferrari M, H Shen H (2014) Bone marrow endothelium-targeted therapeutics for metastatic breast cancer. J Control Release 187:22–29CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Yang X, Bassett SE, Li X, Luxon BA, Herzog NK, Shope RE, Aronson J, Prow TJ, Leary JF, Kirby R, Ellington AD, Gorenstein DG (2002) Construction and selection of bead-bound combinatorial oligonucleotide phosphorothioate and phosphorodithioate aptamer libraries designed for rapid PCR-based sequencing. Nucleic Acids Res 30:e132CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Fetter L, Richards J, Daniel J, Roon L, Rowland TJ, Bonham AJ (2015) Electrochemical aptamer scaffold biosensors for detection of botulism and ricin toxins. Chem Commun 51(82):15137–15140CrossRefGoogle Scholar
  31. 31.
    Zeidan E, Shivaji R, Henrich VC, Sandros MG (2016) Nano-SPRi aptasensor for the detection of progesterone in buffer. Sci Rep. doi:10.1038/srep26714 Google Scholar
  32. 32.
    Lu E, Elizondo-Riojas M-A, Chang JT, Volk DE (2014) Aptaligner: automated software for aligning pseudo-random DNA X-Aptamers from next-generation sequencing data. Biochemistry 53(22):3523–3525CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2017

Authors and Affiliations

  • Ganesh L. Lokesh
    • 1
    • 2
  • Hongyu Wang
    • 1
    • 2
  • Curtis H. Lam
    • 3
  • Varatharasa Thiviyanathan
    • 1
    • 2
  • Nancy Ward
    • 3
  • David G. Gorenstein
    • 3
  • David E. Volk
    • 1
    • 2
  1. 1.Institute of Molecular Medicine for the Prevention of Human DiseasesThe University of Texas Health Science CenterHoustonUSA
  2. 2.Department of Nanomedicine and Biomedical Engineering, McGovern Medical SchoolThe University of Texas Health Science CenterHoustonUSA
  3. 3.AM Biotechnologies, LLCHoustonUSA

Personalised recommendations